IN BRIEF: Indivior unveils profit hike and USD100 million buyback

Indivior PLC - Virginia, US-based opioid-addiction drug maker - Reports first half profit hike ...

Alliance News 29 July, 2021 | 2:37PM
Email Form Facebook Twitter LinkedIn RSS

Indivior PLC - Virginia, US-based opioid-addiction drug maker - Reports first half profit hike and USD100 million buyback. Pretax profit swings to GBP119 million for six months ended June 30 from loss of GBP171 million in same period last year, net revenue climbs 25% to GBP381 million from GBP303 million.

"Looking forward, our number one priority continues to be capturing the full transformational value of SUBLOCADE, and it is gratifying to see further uptake of this key asset in targeted Organized Health Systems, including a USD7 million order from a criminal justice system that we believe is pioneering treatment of incarcerated individuals suffering from opioid use disorder," says Chief Executive Mark Crossley.

No proposed dividend in line with last year. USD100 million share buyback will start shortly with December 31 maturity date.

Current stock price: 156.90 pence, up 5.8% on Thursday afternoon

Year-to-date change: up 44%

By Josie O'Brien; josieobrien@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Indivior PLC 1,400.00 GBX -7.53 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures